The PREEMPT trial analyzed samples from 27,010 average-risk adults to determine the specificity of detecting colorectal cancer ..read more

Data from the phase 1/2 KRYSTAL-1 trial may support adagrasib plus cetuximab as a new standard in previously treated metastatic KRAS G12C–mutated CRC ..read more

Long-term circulating tumor DNA responses appear to align with progression-free survival trends in a phase 2/3 trial of the GRANITE vaccine in those with microsatellite-stable colorectal cancer ..read more

Gut microbiome signatures may lead the way for more accurate treatments and diagnoses for patients with colorectal cancer ..read more

If possible, targeting the BER pathway for drug sensitivities may increase therapeutic options for managing solid cancers, wrote Channing Paller, MD ..read more

Results from part 3 of the phase 2a CORIST trial found that combining SCO-101 with chemotherapy improved the progression-free survival and clinical benefit rate in patients with metastatic colorectal cancer ..read more

Investigators of the AMPLIFY-201 trial hypothesized that ELI-002 2P may induce the expansion of functional tumor-directed KRAS-mutated specific T cells following tumor resection ..read more

Panitumumab plus modified FOLFOX6 appears to increase survival among patients with metastatic colorectal cancer and circulating tumor DNA that has no gene alterations in the PARADIGM trial ..read more

The FDA has set a Prescription Drug User Fee Act date of June 21, 2024 for adagrasib plus cetuximab as a treatment for patients with previously treated KRAS G12C-mutated colorectal cancer ..read more

The Future of BRAF-Mutant mCRC Management Survival following relapse appears to be shorter in patients with stage III colon cancer harboring KRAS exon 2 and BRAF V600E mutations regardless of microsatellite stability status. Christina S. Wu, MB, BCh, MD Christina Wu, MB, BCh, MD, closes the program by expressing the necessity of enrolling patients with BRAF-mutant metastatic colorectal cancer in clinical trials, highlighting a second-line study led by the Southwest Oncology Group, new BRAF inhibitors, early phase studies at the Mayo Clinic, and an exciting study in the adjuvant setting. 2024 M ..read more